Pharmaceutical Analysis & Statistics in Germany, May 2013 (p8)

You might be interested in: therapeutics, drug, cancer, more »

211-260 of about 1 100 reports

Purchase Reports From Reputable Market Research Publishers

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • March 2014
  • by Global Data

V503 (Prophylactic Human Papillomavirus Vaccines) - Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Canada, Spain, Italy, France, Germany, United States, United Kingdom, Europe
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became ...

  • Industries : Drug and Medication
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

  • $ 5 995
  • Industry report
  • March 2014
  • by Global Data

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017 Summary With five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the ...

  • Industries : Pathology
  • Countries : United States, World, Europe, Spain, Italy, France, Germany
EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022

  • $ 3 995
  • Industry report
  • March 2014
  • by Global Data

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022 Summary Ankylosing spondylitis is a systemic, chronic, and progressive inflammatory arthritis in the family of seronegativespondyloarthritis, ...

  • Industries : Pathology
  • Countries : World, United States, Japan, Europe, Sweden, Spain, Italy, France, Germany, Finland
Germany Contrast Media Injectors Market Outlook to 2020

Germany Contrast Media Injectors Market Outlook to 2020

  • $ 2 500
  • Industry report
  • March 2014
  • by Global Data

Germany Contrast Media Injectors Market Outlook to 2020 Summary GlobalData's new report, "Germany Contrast Media Injectors Market Outlook to 2020", provides key market data on the Germany Contrast Media ...

  • Industries : Drug Delivery Technology
  • Countries : Germany
Pharmaceutical Product Development, LLC - Strategic SWOT Analysis Review

Pharmaceutical Product Development, LLC - Strategic SWOT Analysis Review

  • $ 125
  • Company report
  • March 2014
  • by Global Data

Pharmaceutical Product Development, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains ...

  • Industries : Drug Discovery and Development
  • Countries : Germany
PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • February 2014
  • by Global Data

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, United Kingdom, Europe
Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, Japan, World, Europe, United States, United Kingdom
Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States
Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States, United Kingdom
Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Invega (Schizophrenia) - Forecast and Market Analysis to 2022

Invega (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Invega (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Apriso (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Apriso (Ulcerative Colitis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Apriso (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's ...

  • Industries : Pathology
  • Countries : United States, Spain, Germany, India, China, World, Canada, United Kingdom, Japan
Lialda (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Lialda (Ulcerative Colitis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Lialda (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's ...

  • Industries : Pathology
  • Countries : Canada, Japan, United States, Spain, Italy, Germany, World, United Kingdom, North America, Europe
PharmaPoint: Ulcerative Colitis - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Ulcerative Colitis - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • February 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - 5EU Drug Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson ...

  • Industries : Pathology
  • Countries : Italy, Spain, France, Germany, United Kingdom, Europe
Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's ...

  • Industries : Pathology
  • Countries : Canada, United States, Spain, Italy, France, Germany, World, United Kingdom, Japan, Europe, North America
Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's ...

  • Industries : Pathology
  • Countries : Canada, Japan, United States, Spain, Italy, France, Germany, World, United Kingdom, Europe
Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's ...

  • Industries : Pathology
  • Countries : Canada, Japan, United States, Spain, Italy, France, Germany, World, United Kingdom, Europe
Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, United States, Canada, United Kingdom, Japan, World, Europe
Humira (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Humira (Ulcerative Colitis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Humira (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's ...

  • Industries : Pathology
  • Countries : Japan, Canada, United States, Spain, Italy, France, Germany, World, Europe, United Kingdom, North America
About 400 reports

Download Unlimited Documents from Trusted Public Sources

Medigene - Company Report, August 2014

  • Medigene Significantly Improves Financial Results for the first ...
  • August 2014
    3 pages
  • Therapy  

    Immunotherapy  

  • Germany  

View report >

22 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Novartis Inc.

Switzerland

Johnson and Johnson

United States

GlaxoSmithKline PLC

United Kingdom

AstraZeneca PLC

United Kingdom

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.